The acquisition of AI-enabled biohacking technology from Ultiself by Gaxos.ai Inc. is likely to be viewed positively by investors, as it represents a strategic move to enhance the company's product offering in the health sector. This technology is expected to accelerate the development of Gaxos.ai's AI-enabled application, offering a more customized approach to diet, nutrition, and tracking capabilities. Such advancements could potentially increase the company's competitive edge and market share, leading to a positive short-term impact on its stock price.